Time to Buy Fibrocell Science Inc (FCSC) After Today’s Significant Increase?

September 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 0.47 in 2016 Q4. Its down 0.03, from 0.5 in 2016Q3. It fall, as 8 investors sold Fibrocell Science Inc shares while 9 reduced holdings. 2 funds opened positions while 6 raised stakes. 23.97 million shares or 3.70% less from 24.89 million shares in 2016Q3 were reported.
Franklin Street Advsrs Nc reported 50,000 shares. Tci Wealth Advsr Inc stated it has 0% in Fibrocell Science Inc (NASDAQ:FCSC). 4,586 are owned by Blackrock. State Street Corporation stated it has 11,300 shares or 0% of all its holdings. Staley Capital Advisers owns 98,500 shares. Manufacturers Life Insurance The holds 0% or 1,780 shares in its portfolio. Blackrock Fund has 0% invested in Fibrocell Science Inc (NASDAQ:FCSC) for 62,925 shares. Tower Research Capital Limited Liability Corporation (Trc), New York-based fund reported 4,386 shares. Goldman Sachs Gp owns 0% invested in Fibrocell Science Inc (NASDAQ:FCSC) for 109,558 shares. Northern Trust invested 0% of its portfolio in Fibrocell Science Inc (NASDAQ:FCSC). 42 were reported by Walleye Trading Limited Liability Corp. Morgan Stanley stated it has 0% in Fibrocell Science Inc (NASDAQ:FCSC). Blackrock Institutional Tru Na reported 136,333 shares stake. Kcg Holdg holds 63,087 shares or 0% of its portfolio. Kansas-based Creative Planning has invested 0% in Fibrocell Science Inc (NASDAQ:FCSC).

The stock of Fibrocell Science Inc (NASDAQ:FCSC) is a huge mover today! The stock increased 5.96% or $0.19 on September 15, reaching $3.38. About 114,100 shares traded or 61.32% up from the average. Fibrocell Science Inc (NASDAQ:FCSC) has declined 57.80% since September 17, 2016 and is downtrending. It has underperformed by 74.50% the S&P500.
The move comes after 7 months positive chart setup for the $49.74M company. It was reported on Sep, 17 by Barchart.com. We have $3.58 PT which if reached, will make NASDAQ:FCSC worth $2.98 million more.

Analysts expect Fibrocell Science Inc (NASDAQ:FCSC) to report $-0.41 EPS on November, 2.They anticipate $0.05 EPS change or 13.89 % from last quarter’s $-0.36 EPS. After having $-0.31 EPS previously, Fibrocell Science Inc’s analysts see 32.26 % EPS growth.

Fibrocell Science Inc (NASDAQ:FCSC) Ratings Coverage

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 7 analyst reports since September 28, 2015 according to SRatingsIntel. The company was maintained on Friday, June 9 by H.C. Wainwright. Wedbush downgraded the shares of FCSC in report on Monday, September 28 to “Neutral” rating. Roth Capital initiated Fibrocell Science Inc (NASDAQ:FCSC) rating on Tuesday, December 22. Roth Capital has “Buy” rating and $14 target. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. TH Capital initiated the shares of FCSC in report on Tuesday, December 22 with “Buy” rating.

More notable recent Fibrocell Science Inc (NASDAQ:FCSC) news were published by: Zacks.com which released: “Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9% June 20, 2017” on June 20, 2017, also Globenewswire.com with their article: “Fibrocell Reports 2016 Financial Results and Recent Operational Highlights” published on March 09, 2017, Globenewswire.com published: “Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief …” on March 18, 2015. More interesting news about Fibrocell Science Inc (NASDAQ:FCSC) were released by: Globenewswire.com and their article: “Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational …” published on May 10, 2017 as well as Seekingalpha.com‘s news article titled: “Fibrocell Science’s (FCSC) CEO John Maslowski on Q2 2017 Results – Earnings …” with publication date: August 11, 2017.

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has market cap of $49.74 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.